ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade

N. O'Neill,1 T. Zhang,1 W. Sun,1 G. Braileanu,1 X. Cheng,1 I. Tatarov,1 W. Hassanein,1 Z. Habibabady,1 B. Cerel,1 K. Reimann,2 A. Azimzadeh,1 R. Pierson.1

1Surgery, University of Maryland School of Medicine, Baltimore, MD
2University of Massachusetts Medical School, Boston, MA.

Meeting: 2018 American Transplant Congress

Abstract number: D9

Keywords: Alloantibodies, B cells, Co-stimulation, Primates

Session Information

Session Name: Poster Session D: B-cell / Antibody

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Purpose: Because anti-donor alloantibody (alloAb) elaboration is associated with chronic allograft rejection, peri-transplant B cell depletion is being explored to modulate pathogenic alloimmunity. Here, we evaluate an αCD20 agent specifically developed for use in non-human primates to evaluate preemptive B cell depletion in the context of selective αCD28 blockade.

Methods: Cynomolgus monkey MHC-mismatched heterotopic cardiac allograft transplant recipients were treated for 3 months with a selective non-activating αCD28 (FR104, n=12). Five of the 12 additionally received RhαCD20 (Rhesus recombinant IgG; NHP Resource) on d-1 and d21. αCD28 receptor coverage, alloAb production, and B cell phenotypes [naïve (IgD+CD27–), transitional (IgD+CD27–CD38+IgM+), isotype switched memory (IgD–CD27+), and non-switched memory (IgD+CD27+)], were monitored by flow cytometry at regular intervals.

Results: 100% CD28 receptor coverage was consistently achieved through d90. With RhαCD20, peripheral blood B cells were reduced to <1% of baseline by d0 (day of transplant), and remained <10% of baseline for >2-3 months. Three of 7 animals treated with αCD28 monotherapy, but none receiving αCD20+αCD28, rejected during αCD28 treatment. In the αCD20-treated animals, recovery in B cell counts to ≥10% of baseline preceded or coincided with detection of anti-donor IgM and IgG alloAb and graft rejection, which occurred consistently by 130d (range 50-144d). In contrast, alloAb elaboration and graft loss were only observed after 150d (range 150-180d) in the four αCD28-treated recipients that did not reject during αCD28 monotherapy treatment. All grafts failed due to CAV in association with alloAb.

Conclusions: Efficient, durable preemptive B cell depletion using RhαCD20 prevents graft rejection during αCD28 treatment, as previously shown in this model in conjunction with CsA and αCD154 regimens. Our observations suggest that B cell depletion may also interfere with emergence of graft-protective immunomodulation that develops in some recipients with αCD28 treatment. Both preemptive B cell depletion and selective non-activating αCD28 blockade deserve further evaluation to prevent pathogenic alloimmunity, alloAb elaboration, and chronic allograft vasculopathy.

CITATION INFORMATION: O'Neill N., Zhang T., Sun W., Braileanu G., Cheng X., Tatarov I., Hassanein W., Habibabady Z., Cerel B., Reimann K., Azimzadeh A., Pierson R. Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

O'Neill N, Zhang T, Sun W, Braileanu G, Cheng X, Tatarov I, Hassanein W, Habibabady Z, Cerel B, Reimann K, Azimzadeh A, Pierson R. Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade [abstract]. https://atcmeetingabstracts.com/abstract/preemptive-b-cell-depletion-modulates-pathogenic-alloimmunity-associated-with-selective-non-activating-cd28-blockade/. Accessed May 31, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences